enGene Therapeutics (ENGN) Other Non-Current Assets (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Other Non-Current Assets of $1.4 million for Q2 2026, little changed year-over-year from $1.4 million in Q2 2025, and down 0.72% quarter-over-quarter from $1.4 million in Q1 2026.
enGene Therapeutics (ENGN) Other Non-Current Assets (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Other Non-Current Assets for 5 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets changed 0.0% year-over-year to $1.4 million; the TTM figure through Apr 2026 stood at $1.4 million (changed 0.0% YoY), while the FY2025 annual figure was $1.4 million, down 0.87% from the prior year.
- Other Non-Current Assets eased to $1.4 million in Q2 2026 per ENGN's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.6 million in Q1 2025 and bottomed at $930000.0 in Q4 2023.
- Historically, Other Non-Current Assets has averaged $1.3 million across 5 years, with a median of $1.4 million in 2024.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets soared 61.81% — and 2026, when it retreated 12.12%.
- enGene Therapeutics' Other Non-Current Assets stood at $939000.0 in 2022, then retreated by 0.96% to $930000.0 in 2023, then surged by 47.74% to $1.4 million in 2024, then declined by 0.87% to $1.4 million in 2025, then gained by 0.95% to $1.4 million in 2026.
- Business Quant data shows ENGN's Other Non-Current Assets at $1.4 million in Q2 2026, $1.4 million in Q1 2026, and $1.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 1.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.38 Mn |
| Jan 31, 2026 | 1.39 Mn |
| Oct 31, 2025 | 1.36 Mn |
| Jul 31, 2025 | 1.38 Mn |
| Apr 30, 2025 | 1.38 Mn |
| Jan 31, 2025 | 1.58 Mn |
| Oct 31, 2024 | 1.37 Mn |
| Jul 31, 2024 | 1.38 Mn |
| Apr 30, 2024 | 975,000.00 |
| Jan 31, 2024 | 974,000.00 |
| Oct 31, 2023 | 930,000.00 |
| Oct 31, 2022 | 939,000.00 |